Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Ustekinumab use common in psoriasis

20 Dec 2019

Ustekinumab is the biologic therapy most commonly used among patients with psoriasis, though its survival is better among those who are treatment-naïve, a new study has shown.

Researchers conducted a retrospective analysis of 195 psoriasis patients (mean age at first biologic administration, 51.3±14.5 years; 65.6 percent male) who had moderate-to-severe disease. Treatment response was assessed according to the Psoriasis Area and Severity Index (PASI). Treatments that could sustain response for up to 4 months were deemed effective. The switching of biologic therapy was also documented.

Majority (90.6 percent) of the participants achieved a reduction of 75 percent in PASI scores (PASI 75); 72.6 percent and 68.4 percent achieved PASI 90 and PASI 100, respectively.

Ustekinumab was the most commonly used biologic agent in the study (27.8 percent; n=47), followed by etanercept, adalimumab, secukinumab and infliximab. More than half (54.9 percent; n=195) changed agents at least once; 32.3 percent (n=63) switched once, 12.3 percent (n=24) switched twice and 10.3 percent (n=20) switched at least thrice.

The median overall drug survival in treatment-naïve patients was highest for etanercept, at 3.2 years. This was followed by adalimumab (2.8 years) and infliximab (2.5 years). Survival calculations for ustekinumab and secukinumab were impossible due to their later entry to the market. In this subpopulation, ustekinumab had a survival of >7.0 years and secukinumab of >1.8 years.

In patients who had previously been treated, survival rates of the different biologics were comparable. However, each previously used biologic agent significantly increased the likelihood of a subsequent switch by 20 percent.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.